Literature DB >> 16690489

Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.

Xiaohui Zhao1, Qin Huang, Marilyn Slovak, Lawrence Weiss.   

Abstract

Morphologic determination of residual plasma cell myeloma is often difficult. This study was conducted to evaluate the diagnostic value of several ancillary methods. A total of 121 bone marrow specimens from patients with myeloma after bone marrow transplantation or chemotherapy were studied. Of those, 49 cases were studied by conventional cytogenetics (CC), 86 by flow cytometry (FC), 50 by immunohistochemical analysis, 72 by molecular studies (MS) for immunoglobulin gene rearrangements, and 18 by standard fluorescence in situ hybridization (FISH) study. Of the patients, 70 were found to have residual myeloma. Residual disease was detected in 58 of 70 patients by morphologic examination (detection rate, 83%), 25 of 26 by immunohistochemical analysis (96%), 39 of 54 by FC (72%), 6 of 40 by CC (15%), 6 of 12 by FISH (50%), and 24 of 40 by MS (60%). Among the ancillary studies, immunohistochemical analysis and FC were the most helpful ancillary studies for detection of residual disease in myeloma, with immunohistochemical analysis the most effective single method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690489     DOI: 10.1309/B2P9-XEH4-4CY9-LPUK

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

Review 1.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors:  Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal:  Bone Marrow Transplant       Date:  2020-01-28       Impact factor: 5.483

3.  Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.

Authors:  Suzane Dal Bó; Annelise Pezzi; Bruna Amorin; Vanessa Valim; Rosane Isabel Bittencourt; Lucia Silla
Journal:  ISRN Hematol       Date:  2013-06-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.